Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
A phase 3 trial of Abiraterone acetate, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin / leuprolide, Histrelin, Leuprolide, Nilutamide, Prednisone and Triptorelin in Prostate cancer, run by SWOG Cancer Research Network, now recruiting.
Overview
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer is a phase 3 interventional study registered as NCT03678025 by SWOG Cancer Research Network, with 1273 participants planned, started 2018-09-24 and due to reach its primary completion in 2028-04-01. Interventions recorded: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin Acetate, Histrelin Acetate, Leuprolide Acetate, Nilutamide, Orchiectomy, Prednisone, Quality-of-Life Assessment, Radiation Therapy, Radical Prostatectomy, Triptorelin. Conditions recorded: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8.
Linked to the drug Flutamide because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialTwo Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Shares Histrelin, Flutamide, Degarelix, Triptorelin and the tag pipeline.
- TrialHormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
Shares Nilutamide, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialHormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
Shares Nilutamide, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialRadiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Shares Flutamide, Degarelix, Triptorelin, Bicalutamide and the tag pipeline.
- TrialProstate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Shares Flutamide, Triptorelin, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialAssessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Shares Degarelix, Triptorelin, Bicalutamide, Leuprolide (leuprorelin) and GnRH agonists and the tag pipeline.
- TrialFlutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
Shares Flutamide, Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists, Prostate cancer and the tag pipeline.
- TrialTreating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Shares Degarelix, Triptorelin, Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists and the tag pipeline.